anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIM: To evaluate the synergistic effect of combined treatment with melatonin (MEL) and resveratrol (RES) in cisplatin (CIS)-induced premature ovarian failure (POF) model in rats and to elucidate the molecular mechanism of this therapeutic effect.
MATERIAL & METHODS: Female Sprague Dawley rats were divided into 7 experimental groups as follows; CONT (Control), CIS, MEL, RES, POF + MEL, POF + RES, and POF + MEL + RES. H&E staining was performed to evaluate follicular cell vacuolization/degeneration, vascular congestion/hemorrhage, and inflammation, by using an ordinal scale from 0 to 4 to grade the severity of observed changes (0 = normal, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe). Zona pellucida integrity and connective tissue amount in the ovarian tissue were detected using PAS & Masson Trichrome staining. The immunofluorescence method was used to determine the immune localizations of pH2Ax, SIRT1, FOXO3a, and BCL2. The connective tissue amounts and immunoreactivity staining intensities were measured using ImageJ. The gene expression of SIRT1, FOXO3a, and BCL2 was determined using RT-PCR. Serum estrogen hormone levels were measured by ELISA. Statistically, Bonferroni correction was performed, and p < 0.002 were considered significant.
RESULTS: A significant difference was observed in the POF group compared to the CONT group in all parameters except tertiary follicle count and hemorrhage. The decrease in the number of atretic follicles in the POF + MEL + RES group was found significant compared to both POF + MEL and POF + RES groups. The expression of pH2Ax, SIRT1, FOXO3a, and BCL2 at the protein level and SIRT1 and BCL2 at the mRNA level were significant in the POF + MEL + RES group compared to the POF group. Between the single and combination treatment groups, the difference in protein level was found in pH2Ax, SIRT1, FOXO3a, and BCL2 expression. The POF + MEL + RES group exhibited significantly higher SIRT1 mRNA expression compared to the groups receiving single treatments.
CONCLUSION: The present study provides evidence that MEL and RES have synergistic effects in preventing the decrease in follicle reserve and increase in DNA break (pH2Ax) and follicle atresia in POF ovaries. This therapeutic effect is mediated by SIRT1 overexpression and activation of the SIRT1/FOXO3a/BCL2 pathway.
7β-acylamidoceph-3-em-4-carboxylic acids and 6β-acylamidopenam-3-carboxylic acid, and their alk. salts or acid salts, esters and sulfoxides with antibacterial activity and high stability to β-lactamase, were synthesized.  7-aminoceph-3-em-4-carboxylic acid or 6-aminopenam-3-carboxylic acid was related with acylating agent at -20-20≰C in the inactive inog. solvent to give syn- or anti- isomer, or the mixt. contg. more than 75% one isomer.
The dose of verapamil hydrochloride extended-release capsules should be individualized by titration. The usual daily dose of extended-release, verapamil hydrochloride capsules, in clinical trials has been 240 mg given by mouth once daily in the morning. However, initial doses of 120 mg a day may be warranted in patients who may have an increased response to verapamil (e.g., elderly, small people, etc.). Upward titration should be based on therapeutic efficacy and safety evaluated approximately 24 hours after dosing. The antihypertensive effects of verapamil hydrochloride extended-release capsules are evident within the first week of therapy.

If adequate response is not obtained with 120 mg of verapamil hydrochloride extended-release capsules, the dose may be titrated upward in the following manner:

  1. 180 mg in the morning.
  2. 240 mg in the morning.
  3. 360 mg in the morning.
  4. 480 mg in the morning.



Verapamil extended-release capsules are for once-a-day administration. When switching from immediate-release verapamil to verapamil hydrochloride extended-release capsules, the same total daily dose of verapamil hydrochloride extended-release capsules can be used.

As with immediate-release verapamil, dosages of verapamil hydrochloride extended-release capsules should be individualized and titration may be needed in some patients.
Tebentafusp, a bispecific immune therapy, is the only drug that demonstrated an overall survival benefit in patients with metastatic uveal melanoma (MUM). Circulating tumor DNA (ctDNA) has emerged as a potential prognostic and predictive marker in the phase 3 IMCgp100-202 trial using multiplex PCR-based next-generation sequencing (NGS). In this study (NCT02866149), ctDNA dynamics were assessed using droplet digital PCR (ddPCR) in 69 MUM patients undergoing tebentafusp treatment. Notably, 61% of patients exhibited detectable ctDNA before treatment initiation, which was associated with shorter overall survival (median 12.9 months versus 40.5 months for patients with undetectable ctDNA; p < 0.001). Patients manifesting a 90% or greater reduction in ctDNA levels at 12 weeks demonstrated markedly prolonged overall survival (median 21.2 months versus 12.9 months; p = 0.02). Our findings highlight the potential of ddPCR-based ctDNA monitoring as an economical, pragmatic and informative approach in MUM management, offering valuable insights into treatment response and prognosis.
Subjects received Haloperidol Tablets 2 mg Reference Product (Mylan Pharmaceuticals Inc.). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Up to eight cycles of pembrolizumab will be given during the initial induction phase. Each cycle is 21 days. Decitabine will be administered at a dose of 20 mg/m\^2 by intravenous infusion over approximately 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7) for treatment relapsed/refractory AML.
In the concurrent radiochemotherapy group, patients will undergo target delineation based on the scope before induction chemotherapy. Radiotherapy will be administered at a total dose of 70 Gy over 35 fractions, and concurrent chemotherapy will involve weekly administration of cisplatin. Starting three weeks after the completion of radiotherapy, patients will receive adjuvant immunotherapy using a specific protocol of toripalimab at a dose of 240 mg every 3 weeks for a total of 8 cycles.
The systems and methods described herein generally relate to adjusting a neurostimulation (NS) therapy based on drug pharmacokinetics of a patient. The systems and methods deliver an NS therapy to a portion of electrodes of a lead positioned proximate to neural tissue of interest, which is associated with a target region. The NS therapy is defined by stimulation parameters. The systems and methods determine a trigger event indicative of a drug being administered to a patient. The drug is configured to affect at least one of the neural tissue of interest or the target region. The systems and methods adjust one or more of the stimulation parameters based on the PS profile.
In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
PURPOSE:To provide a hair-growing and raising cosmetic containing an oxidizing agent comprising either or both of sodium perborate and sodium percarbonate, inhibiting the oxidation action of 5alpha-reductase, and persisting the effect for a long period. CONSTITUTION:A hair-growing and raising cosmetic is characterized by containing at least one of sodium perborate and sodium percarbonate as an oxidizing agent. The oxidizing agent is preferably added in an amount of approximately 0.01-0.05% based on the whole amount of the cosmetic. The cosmetic contains not only the oxidizing agent but also suitably a galenical ingredient having a fat-activating action, a thickening agent, a solvent, etc., and is diluted with purified water. The galenical ingredient includes the extracts of Panax ginseng, Glycyrrhiza glabra L., SHOKYO (a plant), Luffa cylindrica, and Chamaeyparis obtusa. The oxidizing agent contained in the cosmetic inhibits a reductase, 5alpha-reductase, prevents the conversion of testosterone into 5alpha- dehydrotestosterone (a strong androgenic hormone), and suitably controls the secretion of fats. The oxidizing agent does not decompose the galenical ingredient, etc.
To provide a medial guide to doctors, patients, general users, and medical institutes. The following steps are executed in a medical guide system of the invention. Data on a medical card where examination data including examination items, examination dates and times, and examination results and therapy data including therapies, therapy dates and times, and therapy results are electronically recorded for each patient. Pre-division point data which is the examination data before a predetermined division point in time series of the medical card data and post-division point data which is the examination data after the predetermined division point are extracted for each patient. Therapy patterns with frequencies equal to or higher than a predetermined frequency are extracted from time post-division point data. A rule to associate the examination results with the therapy patterns is derived from the therapy patterns and pre-division point data.
BACKGROUND: The number of coronavirus disease-19 (COVID-19) positive patients and fatalities keeps rising. It is important to recognize risk factors for severe outcomes. Evidence linking vitamin D deficiency and the severity of COVID-19 is tangential but substantial - relating to race, obesity, and institutionalization.
OBJECTIVE: This study aims to examine the function of vitamin D and nutritional defense against infections such as COVID-19, which is the goal of this research.
METHODS: This study includes observational cohort, cross-sectional, and case-control studies that estimated variances in serum levels of vitamin D among patients with mild or severe forms of COVID-19, and in patients who died or were discharged from hospitals. Studies that assessed the risk of developing severe disorder or death in patients with vitamin D deficiency, defined as levels of vitamin D< 20 ng/mL, were also encompassed.
RESULTS: In a retrospective study on 464,383 individuals, results showed that individuals who had the highest risks for severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection, and for COVID-19 severity when infected, had vitamin D levels < 30 nmol/L; Odds Ratio (OR) were 1.246 [95% Confidence Interval (CI): 1.210-1.304] and 1.513 [95%CI: 1.230-1.861], respectively. Additionally, in a retrospective observational study of 191,779 individuals in the USA. The SARS-CoV-2 positivity rate was greater in the 39,190 subjects with vitamin D < 20 ng/mL [12.5%, 95% C.I. 12.2-12.8%] than in the 27,870 subjects with sufficient serum vitamin D levels [8.1%, 95% C.I. 7.8-8.4%] and in the 12,321 subjects with serum vitamin D ⩾ 55 ng/mL [5.9%, 95% C.I. 5.5-6.4%].
CONCLUSION: People hospitalized for COVID-19 should be checked for vitamin D status and supplemented, and high-dose-in testing should be considered in the recovery trial. More importantly, screening for malnutrition and the administration of the best nutritional supplements are essential for the immune system of the human body to function as it should be. Thus, nutritional supplementation is crucial for people with risk factors as well as older adults with compromised immune systems.
The invention discloses a Chinese patent medicament and a Chinese decoction for treating initial carbuncle, belonging to the fields of biology and medicine. The Chinese patent medicament and the Chinese decoction are characterized by being prepared from eleven types of traditional Chinese medicines in a Chinese medicinal formula. The invention has the advantages: the formula belongs to a folk prescription for treating initial carbuncle. As proved, the Chinese decoction has a good healing effect on initial carbuncle. The Chinese medicinal folk prescription can be prepared into pills, powder, granules, tablets, capsules and the like of the Chinese patent medicament, so that the advantages of the Chinese patent medicament are brought into play. The Chinese patent medicament and the Chinese decoction are readily available, adapt to urgent demands, are convenient to store, and can be carried along. The research of the Chinese decoction and the Chinese patent medicament has great commercial development prospect.
Histidine has been found to be efficacious in preventing ischemic/reperfusion induced myocardial injury both functionally and ultrastructurally. Isolated perfused rat hearts (n=8/group) were subjected to 30 minutes of global ischemia and 20 minutes of reperfusion. Histidine concentrations ranging from 10 to 50 mM were given throughout the experiment. During ischemia and reperfusion without histidine the contractile function and coronary flow were 59+/-10% and 78+/-6% of control, respectively. Perfusion with histidine (25 mM and above) resulted in significant increases in contractility (94+/-4%) and coronary flow (92+/-4) levels. The incidence of arrhythmias (ventricular tachycardia and ventricular fibrillation) during reperfusion was 100 percent (8/8) in the ischemic/reperfused group with an average duration of 13.23+/-4.48 min. The addition of 25 mM histidine to the perfusion medium reduced the incidence and duration of arrhythmias significantly (mean+/-SEM 2.25+/-0.98 min) (P<0.01). The protective effects of histidine (25 mM and 50 mM) were significantly better than SOD/catalase/mannitol. Histidine has also been found to significantly reduce the infarct size and the occurrence of arrhythmias in vivo.
Major surgery are operations that can cause morbidity and mortality. Worldwide, approximately 230 million major surgical interventions are performed each year. Major surgery is a stressful experience and causes life-threatening fear and anxiety by increasing the level of anxiety. The most important of these fears is the pain that may occur after surgery. More than 75% of patients who experience postoperative pain in the Western world report that they experience moderate to severe pain. In our country, this rate is over 90%. If pain management is inadequate, patients' quality of life is adversely affected. In pain management, nurses can use non-pharmacological methods such as massage and exercise in addition to pharmacological applications.

Leg-arm exercises done in bed are aimed at protecting the muscle strength of individuals. Turning in bed, leg-arm exercises, raising the heels and feet, inverting the arms, moving from right to left, reverse arm and leg movements are performed. Also 6-8. Early ambulation is recommended. If these applications are made, early recovery and rapid discharge can be achieved. Since pain and anxiety delay early recovery in patients undergoing major surgery, effective pain management is very important. In this study, we aimed to examine the effects of in-bed exercises on anxiety and pain in patients undergoing major surgery.
The value of precise dual energy X-ray absorptiometry (DEXA) cut weight predictions to lamb allocation to cut plans is unknown. Lambs (n = 191) varying in carcase weight (HSCW) and GR (tissue depth over the 12th rib) were DEXA scanned and boned out to weigh retail cuts. Cut weights were predicted using HSCW; HSCW + GR; HSCW + DEXA and HSCW + DEXA image components in GLM models. DEXA improved cut weight predictions in most cuts (P < 0.05). A dataset of 10,000 carcases was then simulated using the associations between HSCW, GR and cut weights, before being truncated to 4500 lambs representing onel day's HSCW distribution. A lamb Carcase Optimisation Tool scenario was developed with 2-3 cut options per carcase section and cut weight thresholds applied to several cuts. Processing costs, market values and actual cut weights were input into the Optimiser to determine carcase allocation to cut options for optimised profits. This scenario was repeated using the predicted cut weights to determine the cut misallocations caused. DEXA-predicted cut weights produced 16.7% and 8.0% less misallocations than HSCW and GR. DEXA produced 20.8% and 14.3% less misallocations than HSCW and GR in shortloins, and 25.5% and 12.9% less in hindquarters. While cut misallocations have little direct impact on total profits, as product is over and under-valued when misallocated, reducing cut misallocations will improve processor compliance when sorting carcases into cut plans- reducing their need to retrim, downgrade and repackage product or the erosion of customer confidence caused by supplying product not meeting market specifications.
An apparatus and method for remote saliva testing in a variety of environments. The test involves the healthcare provider and the patient. Included is a non-invasive method of saliva collection and result detection which allows healthcare providers to send test kits to patient homes for remote testing, monitoring and care decisions. The apparatus includes a dental saliva imaging test card paired with a web application downloaded to a smartphone. The system may be used at home or in the dental office. The smartphone interface walks patients and providers through the test with tutorials to accurately capture testing results. The imaging test card includes a plurality of test strips onto which the patient places saliva. The test strips are sensitized to look for certain biomarkers, some of which detect periodontal disease and elevated caries risk. Results from the test strips are photographed and are then uploaded to the application for analysis.
PURPOSE:To provide the titled water-based coating liquid, by dispersing an alkali metal salt of an acid having a specific acid dissociation constant and a specific water-insoluble hydroxycarboxylic acid cellulose derivative as essential components in water or an aqueous solution of an alcohol. CONSTITUTION:The objective enteric coating liquid is produced by dispersing (A) an alkali metal salt of an acid having an acid dissociation constant (pKa) of >=3 at 25 deg.C (e.g. acetic acid) and (B) a water-insoluble hydroxycarboxylic acid cellulose derivative of formula (Glu is glucose anhydride unit of cellulose and represented by C6H7O2; R1 is H or 1-5C carboxyalkyl; at least one of R2 and R3 is carboxy, etc. when R1 is H) (e.g. carboxymethylethylcellulose) as essential components in (C) water or an aqueous solution of an alcohol containing <=20 wt% 1-3C lower alcohol. The objective water-based enteric coating liquid can be produced highly economically and safely.
Due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended upper dose of amoxicillin is 30 mg/kg/day divided q12h.

a Dosing for infections caused by less susceptible organisms should follow the recommendations for severe infections.

b The children’s dosage is intended for individuals whose weight is less than 40 kg. Children weighing 40 kg or more should be dosed according to the adult recommendations.

After reconstitution, the required amount of suspension should be placed directly on the child’s tongue for swallowing. Alternate means of administration are to add the required amount of suspension to formula, milk, fruit juice, water, ginger ale, or cold drinks. These preparations should then be taken immediately. To be certain the child is receiving full dosage, such preparations should be consumed in entirety.

All patients with gonorrhea should be evaluated for syphilis. (See PRECAUTIONS: Laboratory Tests.)

Larger doses may be required for stubborn or severe infections.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to a new pharmaceutical composition with an enterosoluble coating used for oral administration. Composition has new omeprazole magnesium salt in the new physical form. Invention describes a method of preparing the pharmaceutical composition and a method of treatment of patients with diseases associated with the acid secretion by stomach in mammals and human. EFFECT: new drug form of omeprazole. 18 cl
To address the pharmacokinetic profiles of everolimus and tacrolimus in combination in de novo kidney transplant recipients, comparing 1.5 and 3 mg per day of everolimus in fixed doses. For comparison purposes, pharmacokinetic profiles will be performed at first dose (abbreviated), 4th day, 14th day, and 42nd day post-transplantation. Patients will receive triple therapy steroids, tacrolimus and everolimus. Tacrolimus will be administered at a dose of 0.15 mg/kg/day to achieve 10-15 ng/ml 14 days, and 5-10 thereafter. During the first 6 weeks (the PK study period) everolimus will be assigned to fixed dose of 0.75 or 1.5 mg bid. After day 42, everolimus will be adjusted for 3-8 ng/ml and tacrolimus minimized to optimize graft function. Efficacy and safety parameters at 6 months post-transplantation will be secondary endpoints.
A blood information estimating apparatus that determines a blood status such as a blood pressure of a user is provided. The blood information estimating apparatus  100  includes a data acquiring function  41  serving as a log acquiring unit that acquires a terminal use log of a user terminal such as a mobile terminal and a hypertension detecting function serving as an estimation unit that estimates blood information on change of a blood status based on the terminal use log. The blood information estimating apparatus  100  includes a hypertension detection model that outputs blood information based on the terminal use log. The hypertension detecting function  45  estimates the blood information using the hypertension detection model. With this configuration, it is possible to estimate a blood status of a user without imposing a burden on the user. Accordingly, it is possible to simply estimate a status such as masked hypertension.
FIELD: medicine, chemical-pharmaceutical industry. SUBSTANCE: antiinflammatory and wound-healing agent has carotene-containing preparation, antibacterial agent, methyluracil, Tween-80, synthetic saturated alcohols of primary C 16 -C 21 -fraction, preserving agent, refined water and propellent Chladon-12. Nonaqueous hydrophilic solvent 1,2-propylene glycol or a mixture of glycerol and 95% ethyl alcohol can be used as a preserving agent. Agent provides complex effect on the damaged tissues and high therapeutic effect at simultaneous bacterial impurity control during production process, storage and utilization of the preparation also. EFFECT: enhanced effectiveness of drug proposed. 5 tbl, 3 ex
The present invention provides an extract of Cordyceps militaris mycelium. The extract of Cordyceps militaris mycelium is prepared as the following steps. A substrate is provided, a Cordyceps militaris fungi is provided, a culture process is provided, and an extraction process is provided. After finishing the extraction process, a mixture is separated into solid part and liquid part, wherein the liquid part includes the extract of the Cordyceps militaris mycelium. The extract of Cordyceps militaris mycelium has the abilities of removing superoxide anions and hydroxyl radicals, and inhibiting the peroxidation of lipids. The extract of Cordyceps militaris mycelium can also inhibit growth of breast cancer cells, increase antioxidant enzymes expression of the breast cancer cells, activate tumor suppress proteins and promote the apoptosis of the breast cancer cells, thereby blocking the development of the breast cancer cells.